Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551596 | 1.00 | CA2 (0.47) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL15605968 | 1.00 | CA2 (0.47) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL25928849 | 0.86 | ACE (0.36) | CA2CA4MMEMAPT | |
| SCHEMBL31181187 | 0.84 | CA2 (0.44) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL12426670 | 0.84 | CA2 (0.44) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL14009447 | 0.84 | CA2 (0.44) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL5191274 | 0.84 | ECE1 (0.50) | CA2MMECA1 | |
| SCHEMBL12426218 | 0.82 | RIPK1 (0.44) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL11940951 | 0.82 | RIPK1 (0.44) | CA2CA4MMEFNTAFNTB | |
| SCHEMBL21515914 | 0.81 | ALDH1A1 (0.41) | CA2CA4MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729117-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415328-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CA2 2582/4885CA4 1724/4885MME 398/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CA2 2582/4885CA4 1724/4885MME 398/4885 |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | CA2 4153/4885CA4 4629/4885MME 4177/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CA2 2582/4885CA4 1724/4885MME 398/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CA2 2582/4885CA4 1724/4885MME 398/4885 |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | CA2 3556/4885CA4 2395/4885MME 1854/4885 |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | CA2 3556/4885CA4 2395/4885MME 1854/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | CA2 4339/4885CA4 4584/4885MME 4232/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | CA2 4153/4885CA4 4629/4885MME 4177/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CA2 2582/4885CA4 1724/4885MME 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.